Chaperone Therapy in Fabry Disease

Fabry disease is an X-linked lysosomal multisystem storage disorder induced by a mutation in the alpha-galactosidase A (GLA) gene. Reduced activity or deficiency of alpha-galactosidase A (AGAL) leads to escalating storage of intracellular globotriaosylceramide (GL-3) in numerous organs, including the kidneys, heart and nerve system. The established treatment for 20 years is intravenous enzyme replacement therapy. Lately, oral chaperone therapy was introduced and is a therapeutic alternative in patients with amenable mutations. Early starting of therapy is essential for long-term improvement. This review describes chaperone therapy in Fabry disease.

[1]  R. Schiffmann,et al.  Long-term follow-up of renal function in patients treated with migalastat for Fabry disease , 2021, Molecular genetics and metabolism reports.

[2]  R. Schiffmann,et al.  Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice , 2021, Clinical pharmacology in drug development.

[3]  E. Brand,et al.  Fabry Disease: The Current Treatment Landscape , 2021, Drugs.

[4]  N. Sousa,et al.  Fabry Disease Therapy: State-of-the-Art and Current Challenges , 2020, International journal of molecular sciences.

[5]  E. Brand,et al.  In Vitro and In Vivo Amenability to Migalastat in Fabry Disease , 2020, Molecular therapy. Methods & clinical development.

[6]  I. Olivotto,et al.  Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. , 2020, Molecular genetics and metabolism.

[7]  S. Feriozzi,et al.  Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data , 2020, European Journal of Human Genetics.

[8]  F. Weidemann,et al.  Diagnosis and Screening of Patients with Fabry Disease , 2020, Therapeutics and clinical risk management.

[9]  U. Livi,et al.  Heart transplantation in cardiac storage diseases: data on Fabry disease and cardiac amyloidosis. , 2020, Current opinion in organ transplantation.

[10]  C. Sommer,et al.  Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS) , 2020, Clinical pharmacology and therapeutics.

[11]  S. Feriozzi,et al.  New drugs for the treatment of Anderson–Fabry disease , 2020, Journal of Nephrology.

[12]  M. Langeveld,et al.  Developments in the treatment of Fabry disease , 2020, Journal of inherited metabolic disease.

[13]  M. Cubellis,et al.  Pharmacological Chaperones: A Therapeutic Approach for Diseases Caused by Destabilizing Missense Mutations , 2020, International journal of molecular sciences.

[14]  Y. Qiu,et al.  Inter-assay variability influences migalastat amenability assessments among Fabry disease variants. , 2019, Molecular genetics and metabolism.

[15]  C. Niemietz,et al.  Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy , 2019, Journal of Medical Genetics.

[16]  L. Scott,et al.  Migalastat: A Review in Fabry Disease , 2019, Drugs.

[17]  R. Colvin,et al.  Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study , 2019, Genetics in Medicine.

[18]  M. Beer,et al.  Early detection of organ involvement in Fabry disease by biomarker assessment in conjunction with LGE cardiac MRI: results from the SOPHIA study. , 2019, Molecular genetics and metabolism.

[19]  C. Wanner,et al.  Oral Chaperone Therapy Migalastat for Treating Fabry Disease: Enzymatic Response and Serum Biomarker Changes After 1 Year , 2019, Clinical pharmacology and therapeutics.

[20]  Nuala Moran.  FDA approves Galafold, a triumph for Amicus , 2018, Nature Biotechnology.

[21]  J. Oliveira,et al.  European expert consensus statement on therapeutic goals in Fabry disease. , 2018, Molecular genetics and metabolism.

[22]  R. Schiffmann,et al.  Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial , 2018, Orphanet Journal of Rare Diseases.

[23]  C. Eng,et al.  Fabry disease revisited: Management and treatment recommendations for adult patients. , 2018, Molecular genetics and metabolism.

[24]  D. N. Adam,et al.  A Review of Fabry Disease. , 2018, Skin therapy letter.

[25]  H. Williams,et al.  Reduction of podocyte globotriaosylceramide content in adult male patients with Fabry disease with amenable GLA mutations following 6 months of migalastat treatment , 2017, Journal of Medical Genetics.

[26]  C. Rapezzi,et al.  Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy , 2017, PloS one.

[27]  D. Lockhart,et al.  Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study , 2016, Journal of Medical Genetics.

[28]  D. Lockhart,et al.  The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat , 2016, Genetics in Medicine.

[29]  D. Lockhart,et al.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.

[30]  J. Oliveira,et al.  Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. , 2015, Molecular genetics and metabolism.

[31]  R. Hopkin,et al.  Fabry disease in infancy and early childhood: a systematic literature review , 2014, Genetics in Medicine.

[32]  S. Nagueh.  Anderson-Fabry Disease and Other Lysosomal Storage Disorders , 2014, Circulation.

[33]  M. Beer,et al.  Gene Mutations Versus Clinically Relevant Phenotypes: Lyso-Gb3 Defines Fabry Disease , 2014, Circulation. Cardiovascular genetics.

[34]  C. Hollak,et al.  A systematic review on screening for Fabry disease: prevalence of individuals with genetic variants of unknown significance , 2013, Journal of Medical Genetics.

[35]  C. Wanner,et al.  The Fabry cardiomyopathy: models for the cardiologist. , 2011, Annual review of medicine.

[36]  E. McDade,et al.  Frequency of Unrecognized Fabry Disease Among Young European-American and African-American Men With First Ischemic Stroke , 2010, Stroke.

[37]  D. Lockhart,et al.  The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[38]  D. Lockhart,et al.  The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines , 2009, Journal of Inherited Metabolic Disease.

[39]  M. Beck.  Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety , 2009 .

[40]  C. Wanner,et al.  [Division-related function and organ-related therapy in Fabry's disease. An interdisciplinary challenge]. , 2009, Medizinische Klinik.

[41]  J. Miyazaki,et al.  Novel mutations of the GLA gene in Japanese patients with Fabry disease and their functional characterization by active site specific chaperone , 2008, Human mutation.

[42]  J. Zamorano,et al.  Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. , 2007, European heart journal.

[43]  J. Roth,et al.  Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants. , 2006, American journal of physiology. Cell physiology.

[44]  J. Sandstede,et al.  The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. , 2005, European heart journal.

[45]  J. Roth,et al.  A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[46]  S. Packman,et al.  Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy , 2003, Annals of Internal Medicine.

[47]  Robert J. Desnick,et al.  Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. , 2001, The New England journal of medicine.

[48]  S. Ishii,et al.  In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. , 2000, European journal of biochemistry.

[49]  Satoshi Ishii,et al.  Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor , 1999, Nature Medicine.

[50]  Satoshi Ishii,et al.  Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease , 1995 .

[51]  S. Ishii,et al.  Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease. , 1995, Biochemical and biophysical research communications.

[52]  R Kase,et al.  Characterization of a mutant alpha-galactosidase gene product for the late-onset cardiac form of Fabry disease. , 1993, Biochemical and biophysical research communications.

[53]  M. D'urso,et al.  Residual activity of alpha-galactosidase A in Fabry's disease. , 1975, Biochemical genetics.

[54]  R. Brady,et al.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. , 1967, The New England journal of medicine.